Latest Pharmaceutical News
Novartis Pharma Reports Positive Results From Phase II LCZ696 Trial
Novartis Pharma has reported that its investigational product LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), has successfully completed its first large-scale clinical trial, highlighting the potential of the compound in the treatment of hypertension and other cardiovascular diseases.
Published: 17-Mar-2010
Interleukin-7 Promotes T Cell Viability, Trafficking In Sepsis: Cytheris
Cytheris, a clinical stage biopharma company focused on research and development of new therapies for immune modulation, has published data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.
Published: 16-Mar-2010
AstraZeneca Presents New PLATO Sub-Analysis Of CABG Patients At ACC
AstraZeneca has reported results of a new analysis of PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet Brilinta (ticagrelor) within seven days prior to having heart bypass surgery (coronary artery bypass graft, CABG) compared to those who took clopidogrel.
Published: 16-Mar-2010
Novartis Presents Data Of ASPIRE Study At ACC Congress
Novartis has presented data from ASPIRE study (Aliskiren Study in Post-MI patients to Reduce rEmodelling) at American College of Cardiology (ACC) Congress in Atlanta.
Published: 16-Mar-2010
Risedronate Enters Into Phase 3 Clinical Programs In Japan
Ajinomoto and Takeda Pharma (Takeda) have jointly announced that a once-monthly formulation of risedronate sodium hydrate for the treatment of osteoporosis has entered into phase 3 clinical programs in Japan.
Published: 16-Mar-2010
Icagen Releases Positive Results Of Phase IIa ICA-105665 Trial
Icagen has reported positive results of its Phase IIa epilepsy study of ICA-105665, an orally available small molecule KCNQ potassium channel agonist.
Published: 16-Mar-2010
Portola Pharma, Merck Say Betrixaban Reduces Bleeding In Patients With Atrial Fibrillation
Portola Pharma and Merck have said that a mid-stage clinical trial of heart drug candidate betrixaban, an investigational oral direct Factor Xa inhibitor, showed reduced instances of bleeding in certain patients.
Published: 15-Mar-2010
Novartis Reports Preliminary Results Of Navigator Trial
Novartis has reported that results from a study involving more than 9,000 people showed that the high blood pressure medicine Valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT).
Published: 15-Mar-2010
Ipsen Initiates Two Phase II Clinical Studies Of BIM 23A760
Ipsen has initiated dosing in two Phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.
Published: 15-Mar-2010
Genentech Avastin Fails To Meet Primary End Point In Phase III Trial
Genentech, a wholly owned member of the Roche Group, has presented the results of a Phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute (NCI).
Published: 12-Mar-2010
